6533b7d4fe1ef96bd1261f19
RESEARCH PRODUCT
Statins and angiogenesis in non-cardiovascular diseases.
Fatemeh ZahedipourAlexandra E. ButlerManfredi RizzoAmirhossein Sahebkarsubject
PharmacologyCholesterolNeovascularization PathologicCardiovascular DiseasesNeoplasmsDrug DiscoveryHumansHydroxymethylglutaryl-CoA Reductase InhibitorsAngiogenesis Bone disease Brain disease Cancer Cardiovascular Diabetes Ocular disease Preeclampsia Statins Vascularizationdescription
Statins inhibit HMG-CoA reductase by competitively inhibiting the active site of the enzyme, thus preventing cholesterol synthesis and reducing the risk of developing cardiovascular disease. Many pleiotropic effects of statins have been demonstrated that can be either related or unrelated to their cholesterol-lowering ability. Among these effects are their proangiogenic and antiangiogenic properties that could offer new therapeutic applications. In this regard, pro- and anti-angiogenic properties of statins have been shown to be dose dependent. Statins also appear to have a variety of non-cardiovascular angiogenic effects in many diseases, some examples being ocular disease, brain disease, cancer, preeclampsia, diabetes and bone disease, which are discussed in this review using reports from in vitro and in vivo investigations.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-10-01 | Drug discovery today |